Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

YUPELRIPositive

AI Analysis

Summary

Theravance Biopharma reported Q2 2026 results with YUPELRI collaboration revenue increasing 11% year-over-year to $20.7 million. The company's acquisition by Zymeworks is expected to close in the second half of 2026.

Financial Highlights

Revenue

$20.7 million

Outcome Details

Acquisition by Zymeworks expected to close in second half of 2026

Importance:6/10

Sentiment:

0.30

Q2 2026 earningsacquisitionrevenue growthcollaboration revenue

Related Companies

$ZYME

Read the original article

Published by PR Newswire Biotech on August 10, 2026 12:30 PM

Read Original